Contribution of New Pancreatic MRI Sequences for the Evaluation of Tumor Response in Pancreatic Adenocarcinomas

Pancreatic adenocarcinoma is the most pessimistic digestive cancer in terms of prognosis. Tumor response assessment is crucial, and the recent development of new magnetic resonance imaging sequences, such as high resolution applied to diffusion sequences (Harder et al., 2022) or magnetic resonance elastography (MRE) (Steinkohl et al., 2021), could help address this issue.

Trial Details

NCT ID
NCT06842303
Phase
NA
Sponsor
Central Hospital, Nancy, France
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Magnetic resonance elastography (MRE).
  • High-resolution diffusion sequence in MRI
Locations (sample)
  • Vandœuvre-lès-Nancy, France, France|48.66115,6.17114

Key Eligibility Criteria

  • CT scan diagnosis of non-metastatic pancreatic cancer on contrast-enhanced thoraco-abdomino-pelvic CT;
  • Adult patient: age ≥ 18 years;
  • Patient affiliated with a social security system or beneficiary of such a system;
  • Patient who has received complete information about the research organization and has signed an informed consent form.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →